3 results about "Plasma Exchanges" patented technology

The application discloses a plasma replacement device based on pipeline pressure intelligent monitoring and belongs to the technical field of medical instruments. The plasma replacement device based on pipeline pressure intelligent monitoring comprises a side support plate, a clamping block is arranged on the inner side of the side support plate, an extraction pipeline and an input pipeline are respectively arranged on the clamping block, an extrusion assembly is arranged in the middle of the extraction pipeline and the input pipeline, the extraction pipeline is connected with a centrifugal assembly, and the input pipeline is connected with a replacement assembly. The application solves the problem that the prior art cannot detect the pressure of the pipeline, thereby causing the pipeline to leak or the blood flow to be abnormal and the problem that the abnormality cannot be found in time, the application can automatically identify the pipeline leakage or blood flow abnormality risk and timely adjust, the pipeline leakage and blood flow abnormality in the process of plasma replacement cannot be found in time, thereby causing damage to the health of the patient, the monitoring data is consistent with the actual physiological state, and the medical effect of plasma replacement is improved.

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and / or low volume plasma exchange. Also provided are kits suitable for performing such methods.

The present invention relates to a composition comprising albumin for use in the treatment of Amyotrophic Lateral Sclerosis (ALS), wherein the composition is administrated to the patient by plasma exchange using a volume of said composition equivalent to approximately 100 % of the volume of plasma withdrawn from the patient, and with a frequency of twice a week the first 3 weeks and once a week for the following 21 weeks, for a total period of 24 weeks.